SCHEMBL13290996

SCHEMBL13290996

Cc1ccc(NC(=O)c2oc3ccc(F)nc3c2NC(=O)[C@H]2CC[C@H](C(=O)N(C)CCN(C)C)CC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.39
▸ RAB9A P51151 5/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ CASP3 P42574 1/20 0.39
▸ SENP7 Q9BQF6 1/20 0.39
▸ SENP6 Q9GZR1 1/20 0.39
▸ HTR1F P30939 1/20 0.36
▸ TP53 P04637 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ GLA P06280 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290963 0.92 SMN1; SMN2 (0.39) NPC1RAB9AHTR1FTP53POLB
SCHEMBL13290985 0.90 NPC1 (0.42) NPC1RAB9AKMT2ACASP3SENP7
SCHEMBL13291003 0.89 NPC1 (0.42) NPC1RAB9AKMT2ACASP3SENP7
SCHEMBL13291002 0.89 MAPT (0.47) KMT2ATP53MAPTPOLBRXFP1
SCHEMBL13290964 0.85 SMN1; SMN2 (0.39) NPC1RAB9ATP53POLBRXFP1
SCHEMBL13290957 0.85 SMN1; SMN2 (0.41) NPC1RAB9ATP53KDM4EALOX15
SCHEMBL13291009 0.83 KMT2A (0.44) NPC1RAB9AKMT2ACASP3SENP7
SCHEMBL13290922 0.82 KMT2A (0.42) NPC1RAB9AKMT2ACASP3SENP7
SCHEMBL13290780 0.82 SMN1; SMN2 (0.39) NPC1RAB9AKMT2ATP53KDM4E
SCHEMBL13290961 0.82 SMN1; SMN2 (0.42) NPC1RAB9AKMT2ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 NPC1 4426/4885RAB9A 4692/4885KMT2A 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback